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Hisar 125 001, Haryana, India
Cure of cognitive disorders such as amnesia, attention deficit and Alzheimer’s disease isstill a nightmare
in the field of medicine. Nootropic agents such as piracetam, aniracetam and choline esterase inhibitors
like Donepezil  are being used to improve memory, mood and behavior, but the resulting side effects
associated with these agents have made their use limited. The present study was undertaken to assess
the potential of Brahmi rasayana (BR) as a memory enhancer. BR (100 and 200 mg kg
 1 p.o.)
was administered for eight successive days to both young and aged mice. Elevated plus maze and
passive-avoidance paradigm were employed to evaluate learning and memory parameters. Scopolamine
(0.4 mg kg
 1 i.p.) was used to induce amnesia in mice. The effect of BR on whole brain AChE activity
was also assessed. Piracetam (200 mg kg
 1 i.p.) was used as a standard nootropic agent. BR significantly
improved learning and memory in young mice and reversed the amnesia induced by both scopolamine
(0.4 mg kg
 1 i.p.) and natural aging. BR significantly decreased whole brain acetyl cholinesterase activ-
ity. BR might prove to be a useful memory restorative agent in the treatment of dementia seen in elderly.
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Introduction
Alzheimer’s disease is a progressive neurodegenerative brain
disorder that is slow in onset but leads to dementia, unusual
behavior, personality changes and ultimately death (1). The
personality distortions interfere with the patient’s professional
life, social activities and relationships (2).
Nootropic agents such as piracetam (3), pramiracetam,
aniracetam (4) and choline esterase inhibitors like Donepezil 
are being primarily used to improve memory, mood and
behavior. However, the resulting adverse effects associated
with these agents have limited their use (5,6). Therefore, it is
worthwhile to explore the utility of traditional medicines for
the treatment of various cognitive disorders.
Ayurveda is the oldest medical science in the Indian sub-
continent and has been practiced since the 12th Century BC.
Its objective is to accomplish physical, mental, social and
spiritual well-being by adopting preventive, health promoting
and holistic approach towards life (7,8). Vata, pitta and kapha
are the three psychobiological dimensions (energy) or biologi-
cal rhythms regulating the entire functioning of the human
body. Vata, is the energy that strengthens intellectual power,
respiration and the activity of sensory organs. Sadhak Pitta
regulates digestion of food and body temperature and is
responsible for intelligence and memory. Tarpak kafa provides
nutrition to the sense organs and is helpful in lubrications of
the nervous tissue. According to ayurveda, Alzheimer’s dis-
ease is an imbalance of vata, pitta and kapha (9). Medhya
herbs such as Convolvulus pluricaulis, Centella asiatica,
Bacopa monnieri, Acorus calamus and Celastrus paniculatus
are beneficial in cognitive disorders (10).
Rasayanas are ayurvedic preparations that promote resis-
tance against infections and other diseases by maintaining the
equilibrium of vata, pitta and kapha. The rasayanas improve
memory, intelligence and promote youthfulness, good lusture,
complexion and efficiency (11). Various rasayana drugs like
Withania somnifera, Asparagus racemosus and Tinospora
cordifolia have proven their therapeutic worth (10).
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herbal preparation, Brahmi rasayana (BR) were investigated
by employing both exteroceptive and interoceptive models.
The stimulus lies outside the body in the exteroceptive
behavioral models, whereas it lies within the body in case of
the interoceptive behavioral models. Elevated plus maze is a
neutral exteroceptive model used to assess short-term memory,
whereas passive-avoidance apparatus is a punishment-based
exteroceptive model used to test long-term memory (12).
Interoceptive behavioral models such as scopolamine and
natural aging induced amnesia are widely cited as models
simulating human dementia in general and Alzheimer’s
disease in particular.
Methods
BR comprises coarse powders of dried leaves of B. monnieri,
flower buds of Eugenia caryophyllus, seeds of Elettaria
cardamomum, inner bark of shoots of Cinnamomum zeylan-
icum, and fruits of Piper longum and Piper nigrum (13,14).
BR prepared as per standard ayurvedic procedures (15) was
procured from Dindayal ayurvedalaya, India, as a gift sample
and the same were administered in doses of 100 and
200 mg kg
 1 p.o. for eight successive days to the mice.
Drugs and Chemicals
Scopolamine hydrobromide (Sigma Aldrich, USA) and
piracetam (Nootropil ; UCB India Pvt. Ltd, Vapi, Gujarat)
were diluted in normal saline and injected intraperitoneally.
Phenytoin (Dilantin  suspension; Parke Davis) was adminis-
tered orally. Volume of administration was 1 ml per 100 g.
All the drugs were administered in the morning session i.e.
8 a.m.–9 a.m. on each day.
Administration of BR
BR at different doses (50–500 mg kg
 1) was administered
orally to the mice with the help of a specially designed oral
needle connected to a polythene tube. BR was administered
at the same time on each day (i.e. 8 a.m.–9 a.m.). During the
first 4 h after the drug administration, the animals were
observed for gross behavioral changes if any, for 7 days. The
parameters such as hyperactivity, grooming, convulsions,
sedation, hypothermia and mortality were observed. The doses
selected for future studies were 100 and 200 mg kg
 1 per day.
Mice
Swiss mice of either sex weighing  18 g (younger ones, aged
8 weeks) and 25 g (older ones, aged 28 weeks) were used in
the present study. Mice were procured from disease free ani-
mal house of CCS Haryana Agriculture University, Hisar
(Haryana, India). They were acclimatized to the laboratory
conditions for 5 days before behavioral studies. Mice had
free access to food and water and were maintained under 12
h light/12 h dark cycles. All the readings were taken during
the same time of the day i.e. between 8 a.m. and 11 a.m. The
Institutional Animals Ethics Committee (IAEC) had approved
the experimental protocol, and care of animals was taken as
per guidelines of CPCSEA, Department of Animal Welfare,
Government of India.
Exteroceptive Behavioral Models
Elevated Plus Maze
The elevated plus maze served as the exteroceptive behavioral
model (wherein the stimulus existed outside the body) to
evaluate learning and memory in mice. The apparatus con-
sisted of two open arms (16 cm · 5 cm) and two covered
arms (16 cm · 5c m· 12 cm). The arms extended from a cen-
tral platform (5 cm · 5 cm), and the maze was elevated to a
height of 25 cm from the floor. On the first day, each mouse
was placed at the end of an open arm, facing away from the
central platform. Transfer latency (TL) was taken as the time
taken by the mouse to move into any one of the covered
arms with all its four legs. TL was recorded on the first day.
If the mouse did not enter into one of the covered arms within
90 s, it was gently pushed into one of the two covered arms
and the TL was assigned as 90 s. The mouse was allowed to
explore the maze for 10 s and then was returned to its home
cage. Memory retention was examined 24 h after the first
day trial on the second day (16,17).
Passive Shock Avoidance Paradigm
Passive-avoidance behavior based on negative reinforcement
was recorded to examine long-term memory. The apparatus
consisted of a box (27 · 27 · 27 cm
3) having three walls of
wood and one wall of Plexiglas, featuring a grid floor (3 mm
stainless steel rods set 8 mm apart), with a wooden platform
(10 · 7 · 1.7 cm
3) in the center of the grid floor. The box
was illuminated with a 15 W bulb during the experimental
period. Electric shock (20 V AC) was delivered to the grid
floor. Training was carried out in two similar sessions. Each
mouse was gently placed on the wooden platform set in the
center of the grid floor. When the mouse stepped down and
placed all its paws on the grid floor, shocks were delivered
for 15 s and the step-down latency (SDL) was recorded. SDL
was defined as the time taken by the mouse to step down
from wooden platform to grid floor with its entire paw on the
grid floor. Mice showing SDL in the range (2–15 s) during
the first test were used for the second session and the reten-
tion test. The second session was carried out 90 min after
the first test. When mice stepped down before 60 s, electric
shocks were delivered for 15 s. During the second test, animals
were removed from shock free zone if they did not step down
for a period of 60 s. Retention was tested after 24 h in a similar
manner, except that the electric shocks were not applied to the
grid floor. Each mouse was again placed on the platform, and
the SDL was recorded, with an upper cutoff time of 300 s
(18,19).
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Mice were divided into 24 groups and each group consisted of
a minimum of five animals. Separate animals were used for
each experiment.
Group I: It represented the control group for young mice
(n ¼ 6). Distilled water (DW), was administered orally for
8 days. TL was noted after 45 min of administration on the
eighth day and again after 24 h, i.e. on the ninth day.
Groups II and XI: Piracetam, 200 mg kg
 1 i.p. was injected to
both young and aged mice, respectively. TL was noted after
45 min of injection and again after 24 h.
Group III: Scopolamine (0.4 mg kg
 1 i.p.) was administered to
young mice and TL was noted after 45 min of injection on the
eighth day and again after 24 h, i.e. on the ninth day.
Groups IV and V: BR (100 and 200 mg kg
 1) was adminis-
tered orally to young mice for 8 days. The last dose was given
45 min before subjecting the animals to elevated plus maze
test. TL was noted on the eighth day and again after 24 h.
Group VI: BR (200 mg kg
 1 p.o.) was administered to
young mice for 8 days. After 45 min of administration of
the last dose on the eighth day, scopolamine hydrobromide
(0.4 mg kg
 1 i.p.) was administered. TL was noted after
45 min of administration of scopolamine and again after
24 h, i.e. on the ninth day.
Group VII: Piracetam (200 mg kg
 1 p.o.) was administered
to young mice for 8 days. After 45 min of administration of
the last dose on the eighth day, scopolamine hydrobromide
(0.4 mg kg
 1 i.p.) was administered. TL was noted after
45 min of administration of scopolamine and again after
24 h, i.e. on the ninth day.
Group VIII: Served as the control group for aged mice. DW
was administered orally for 8 days. TL was noted after
45 min of administration on the eighth day and again after
24 h, i. e on the ninth day.
Groups IX and X: BR (100 and 100 mg kg
 1) was adminis-
tered orally to aged mice for 8 days. The last dose was given
45 min before noting TL on the eighth day.
Group XII: Control group for young mice (n ¼ 6). DW (1 ml
per 100 g) was administered p.o. for 8 days. After 90 min of
administration on the eighth day, SDL was recorded. Retention
was examined after 24 h.
Groups XIII and XIV (n ¼ 5 each): BR extract (100 and
200 mg kg
 1, respectively) was administered orally for 8 days
to young mice. SDL was recorded after 90 min of administra-
tion on the eighth day and after 24 h.
Group XV: Scopolamine hydro bromide (0.4 mg kg
 1) was
administered i.p. to young mice after training on the eighth
day and SDL was recorded at 45 min after injection.
Group XVI: BR (200 mg kg
 1 p.o.) was administered to
young mice for 8 days. After 45 min of administration of
the last dose on the eighth day, scopolamine hydrobromide
(0.4 mg kg
 1 i.p.) was administered. SDL was recorded after
90 min of administration on the eighth day and after 24 h.
Group XVII: Control group for aged mice (n ¼ 6). DW
(1 ml per 100g) was administered p.o. for 8 days to aged
mice. After 90 min of administration on the eighth day, SDL
was recorded. Retention was examined after 24 h.
Groups XVIII and XIX: BR (100 and 200 mg kg
 1, respec-
tively) was administered orally for 8 days to aged mice. SDL
was recorded after 90 min of administration on the eighth
day and after 24 h.
Group XX: served as control and was treated with saline water,
Group XXI was treated with phenytoin (12 mg kg
 1 p.o.) and
Group XXII was treated with piracetam (200 mg kg
 1 p.o.).
Group XXIII and Group XXIV were treated with BR
(100 and 200 mg kg
 1 p.o., respectively) for 8 days and
acetyl cholinesterase (AChE) levels were determined.
Estimation of Brain AChE Activity
The time frame of cholinesterase activity estimation was simi-
lar to behavioral tests, i.e. 8 a.m.–11 a.m. on each day. On the
ninth day animals were euthanized by cervical dislocation
carefully to avoid any injuries to the tissue. The whole brain
AChE activity was measured using the Ellman method (20).
The end point was the formation of the yellow color because
of the reaction of thiocholine with dithiobisnitrobenzoate
ions. The rate of formation of thiocholine from acetylcholine
iodide in the presence of tissue cholinesterase was measured
using a spectrophotometer. The sample was first treated with
5,50-dithionitrobenzoic acid (DTNB), and the optical density
(OD) of the yellow color compound formed during the reaction
at 412 nm every minute for a period of 3 min was measured.
Protein estimation was done using Folin’s method. AChE
activity was calculated using the following formula:
R ¼
d OD · volume of assay (3 ml)
E · mg of protein
where R is the rate of enzyme activity in ‘n’ mole of acetyl-
choline iodide hydrolyzed per minute per mg of protein.
d OD is the change in absorbance per minute and E is the
extinction coefficient, which is 13600 M
 1 cm
 1.
Statistical Analysis
All the results were expressed as mean ± standard error. The
data were analyzed using ANOVA and Student’s (unpaired)
t-test. Kruskal–Wallis one-way ANOVA followed by multiple
range tests was used for the analysis of non-normally dis-
tributed data. P < 0.05 was considered as significant.
Results and Discussion
Aged mice showed higher TL values on the first day and on
the second day (after 24 h) as compared with young mice,
indicating an impairment in learning and memory. Piracetam
(200 mg kg
 1 i.p.) pre-treatment for 8 days decreased TL of
eighth day and ninth day as compared with distilled water
treated group, indicating improvement in both learning and
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 1) increased TL signifi-
cantly [first day TL: F(11, 51) ¼ 11.760 (P < 0.05); second
day TL: F(11, 51) ¼ 4.122, P < 0.05] in young mice on the
first and the second day as compared with control, indicating
impairment of both learning and memory (Fig. 1).
Higher Dose of BR Improved the Learning and
Memory of Aged Mice
BR (100 mg kg
 1 p.o.) decreased the TL on the eighth day and
the ninth day in both young and aged mice (P < 0.05) when
compared with their respective control groups. Higher dose
of BR (200 mg kg
 1 p.o.) improved learning and memory of
aged mice rather than young mice as reflected by marked
decrease in TL on the eighth day and the ninth day, when sub-
jected to elevated plus maze tests (Fig. 1). BR pre-treatment
for 8 days protected young as well as old mice (P < 0.05)
against scopolamine-induced amnesia.
BR Reversed Amnesia
BR (100 and 200 mg kg
 1 p.o.) treatment profoundly
increased SDL as compared with the control group on the
second day indicating improvement in memory of young
mice. Scopolamine hydrobromide (0.4 mg kg
 1 i.p.) decreased
SDL on second day after training, indicating impairment
of memory. BR (200 mg kg
 1 p.o.) administered orally for
8 days significantly [F(7, 32) ¼ 59.312, P < 0.05] reversed
amnesia induced by scopolamine and natural ageing (Fig. 2).
The acetylcholinesterase activity of whole brain was markedly
elevated (P < 0.05) after phenytoin (12 mg kg
 1 p.o.) treat-
ment. Piracetam (200 mg kg
 1 p.o.) and BR (100 and
200 mg kg
 1 p.o.) significantly (H ¼ 16.67, P < 0.05)
lowered AChE activity (Fig. 3).
Alzheimer’s disease is a neurodegenerative disorder associ-
ated with a decline in cognitive abilities. Patients often show
non-cognitive symptoms, such as depression, apathy and
psychosis that impair their day-to-day activities (21). The pre-
sent study suggests that BR is a potential anti-cholinesterase
agent. It also possesses nootropic activity in view of its facili-
tatory effect on retention of learned task. Central cholinergic
system plays an important role in learning and memory (22).
In our study, phenytoin per se (12 mg kg
 1 p.o.) significantly
elevated brain AChE activity. Piracetam (250 mg kg
 1 p.o.)
and BR (100 and 200 mg kg
 1 p.o.), on the other hand signifi-
cantly (P < 0.05) lowered this activity indicating the counter-
acting actions of these drugs on the cholinergic system. BR
also reversed the scopolamine-induced impairment in learning
and memory, when assessed on passive-avoidance paradigm.
Pharmacological Properties of BR Components
Include Anti-inflammatory, Antioxidant and
Memory Improving Activities
The major components of BR include coarse powders of dried
leaves of B. monnieri, flower buds of E. caryophyllus, seeds
of E. cardamomum, inner bark of shoots of C. zeylanicum
Figure 1. EffectofBRontransferlatenciesofyoungandagedmiceon elevatedplusmaze.Eachgroupcomprisesa minimumoffivemice.Valuesare expressedas
mean ± SEM, ANOVA followed unpaired t-test, *P < 0.05 compared with control (young group),
aP < 0.05 compared with scopolamine treated group,
bP < 0.05 compared with control (aged group), first day TL: F(11, 51) ¼ 11.760 (P < 0.05); second day TL: F(11, 51) ¼ 4.122 (P < 0.05).
82 Brahmi Rasayana enhances memory in miceFigure 2. Effect of BR on SDL using passive-avoidance apparatus. Values are each mean ± SEM, ANOVA followed unpaired t-test, *P < 0.05 compared with
control (young mice),
aP < 0.05 compared with scopolamine treated group alone,
bP < 0.05 compared with control (aged mice alone), SDL: F(7, 32) ¼ 59.312.
Figure 3. Effect of BR on AChE activity in aged mice. Values are mean ± SEM, AChE-whole brain AChE (mmol), *P < 0.05 versus control (multiple range test),
H ¼ 16.67; df ¼ 5; I < 0.05.
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exhibit several pharmacological properties (23). Bacosides of
B. monnieri are reported to potentiate human long-term
memory (24) and exhibit anti-stress activity (23). Administra-
tion of B. monnieri extract to mentally retarded children has
produced beneficial results (25). E. cardamomum was found
to possess anti-inflammatory activity (26) and antioxidant
activity (27). E. caryophyllus is reported to have anti-ulcer
(28), anti-inflammatory (29) and antioxidant activity (30).
P. nigrum and P. longum contain a major alkaloid, piperine,
which possesses antioxidant (31), immunomodulatory (32),
antitumor (33), antimutagenic (34), anticonvulsant (35),
analgesic (36) and memory improving activities (37). Water-
soluble polyphenol polymers from C. zeylanicum exhibited
pro-healing (38), antioxidant activity (39) and reduced
the risk factors associated with diabetes and cardiovascular
diseases (40).
Therefore, the memory improving activity of BR may be
attributed to its antioxidant, anti-inflammatory, neuroprotec-
tive, pro-cholinergic and anti-acetylcholinesterase properties
of various components of the multi-herbal preparation and
hence may be of enormous use in delaying the onset and reduc-
ing the severity of Alzheimer’s disease. However, further
investigations are warranted to explore the possible involve-
ment of other neurotransmitters, such as glutamate, GABA
and catecholamines (41), responsible for memory improving
property of BR.
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